

BUSKOP LAW GROUP, P.C.

PATENT ATTORNEYS
WENDY K. B. BUSKOP
CHRISTIAN N. HEAUSLER

TRADEMARK ATTORNEY
ANISHA S. CHOKSI

EXECUTIVE DIRECTOR
RUTH E. GERNHART

Patents, Trademarks,
Copyrights
&
Related Matters

1717 St. James Place
Suite 500
Houston, TX 77056

Telephone: (713) 403-7411
Fax: (713) 960-0204

www.buskoplaw.com

PARALEGALS
GERTRUD W. BARKER
SARAH A. GERNHART

STAFF
DEBORAH A. CHILDERS
KENYETTA L. GREEN
BABS ROBICHEAUX

WASHINGTON OFFICE
PETER A. BORSARI, OF COUNSEL
2001 JEFFERSON DAVIS HIGHWAY
SUITE 206
ARLINGTON, VA 22202
TEL: 800-225-2462
FAX: 703-415-4635

Writer's Direct Dial:
713.403.7410


March 17, 2004

File No. 1190.14

MAIL STOP DD
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF FIRST CLASS MAIL

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope, addressed to **MAIL STOP DD**, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on the following date: March 17, 2004.


Wendy K. B. Buskop

RE: *U.S. Patent Application Serial No. 10/725,608;*
Entitled: "Supplement for Treating Musculoskeletal Disorders";
Inventors: Kenneth A. Martin and Teresa Leigh Barr.

Sirs:

Enclosed for filing in the above-mentioned application is:

- (1) An Information Disclosure Statement;
- (2) A Form PTO-1449 listing references A1-A11; and
- (3) A postcard. Please date stamp and return the enclosed postcard to evidence receipt of these materials.


BUSKOP LAW GROUP, P.C.

Application Serial No. 10/725,608
March 17, 2004

File No. 1190.14
Page 2 of 2

No fees are believed to be due in connection with these materials. However, the Commissioner is hereby authorized to charge any deficiencies to Deposit Account No 50-1313 in the name of Buskop Law Group. A duplicate copy of this transmittal is enclosed.

Respectfully submitted,


Wendy Buskop
Patent Attorney
Reg. No. 32,202



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Kenneth A. Martin and Teresa Leigh Barr

Serial No.: 10/725,608

Filed: December 02, 2003

For: Supplement for Treating
Musculoskeletal Disorders

Group Art Unit: 1614

Examiner: Not Assigned

Atty Dkt No.: 1190.14

MAIL STOP DD

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

CERTIFICATE OF FIRST CLASS MAIL

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope, addressed to **MAIL STOP DD**, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on the following date: March 17, 2004.

Wendy Buskop
Wendy K. B. Buskop

INFORMATION DISCLOSURE STATEMENT

Sir:

- I. Applicants hereby submit an Information Disclosure Statement and enclose a Form PTO-1449 listing references A1-A11 for consideration by the Examiner. Copies of each listed reference are not enclosed. This application is a Continuation In Part of prior co-pending application 10/241,542 filed on September 11, 2002. The listed references were previously submitted or cited by the Examiner in the related prior co-pending application Serial No. 10/241,542.
- II. Applicants hereby request the Examiner to consider the cited references. As required under 37 C.F.R. § 1.98(a)(3)(i), the following is a concise explanation of the relevance of each reference, as they are presently understood:

Application Serial No.: 10/725,608

Attorney Docket No.: 1190.14

REFERENCE NO. A1 (US 3,686,406): “This invention relates to 2-(2-methylanilino)-nicotinic acid, the non-toxic pharmaceutically acceptable salts thereof and to the methods for the preparation and use thereof.”

REFERENCE NO. A2 (US 4,616,039): “Methylsulfonylmethane is effective in maintaining good health and in improving poor health of animals, including human beings and is an assimilable source of dietetic sulfur.”

REFERENCE NO. A3 (US 4,621,137): “The present invention relates to food products containing a novel alpha-glycosyl ginsenoside wherein one or more alpha-glucosyl moieties are bound to ginsenoside residue, and a process for producing the food products. Such alpha-glycosyl ginsenoside is obtainable by subjecting an aqueous solution of ginsenoside and an alpha-glucosyl saccharide to an alpha-glucosyl transferase.”

REFERENCE NO. A4 (US 5,827,834): “A method of treating anorectal disease is provided which comprises applying to anorectal tissue in need of such treatment an effective amount of a composition comprising a pharmaceutically acceptable carrier and hyaluronic acid or a pharmaceutically acceptable salt thereof in an amount of up to about 10% by weight.”

REFERENCE NO. A5 (US 5,852,002): “A combination for administration to a mammal which combination employs a therapeutically effective amount of a medicinal and/or therapeutic agent to treat a disease or condition and an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and subunits of hyaluronic acid sufficient to facilitate the agent's penetration through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated.”

REFERENCE NO. A6 (US 5,916,565): “A composition and method of use is disclosed that, when administered to an animal, is capable of arresting the inflammatory response in affected tissues and facilitates the repair and maintenance of damaged tissues in the joints of vertebrates. The combination of natural physiological metabolites and herbal phytochemicals is used to treat connective tissue diseases, the composition is preferably orally administered. One embodiment of the composition includes chondroitin sulfate and glucosamine that, when ingested by a vertebrate, suppresses the degradation of connective tissue by an autoimmune response.

A composition of the present invention includes a palatability agent, an herbal phytochemical,

and a metabolic precursor that act to increase blood circulation, thereby enhancing transport of the phytochemical and metabolic precursors to an affected site whereby deleterious inflammatory byproducts are removed.”

REFERENCE NO. A7 (US 5,929,048): “A combination for administration to a mammal which combination employs a therapeutically effective amount of a medicinal and/or therapeutic agent to treat a disease or condition and an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and subunits of hyaluronic acid sufficient to facilitate the agent's penetration through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated.”

REFERENCE NO. A8 (US 5,932,560): “A combination for administration to a mammal which combination employs a therapeutically effective amount of a medicinal and/or therapeutic agent to treat a disease or condition and an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and subunits of hyaluronic acid sufficient to facilitate the agent's penetration through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated.”

REFERENCE NO. A9 (US 6,194,392): “A combination for administration to a mammal which combination employs a therapeutically effective amount of a medicinal and/or therapeutic agent to treat a disease or condition and an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and subunits of hyaluronic acid sufficient to facilitate the agent's penetration through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated.”


REFERENCE NO. A10 (US 6,358,526): “The present invention provides a method of making tablet compositions that are substantially free of excipients. The method includes forming a compactable granular mixture containing at least one compaction enhancing therapeutic compound, at least one other therapeutic compound that is different from the compaction enhancing therapeutic compound, and less than about 15 weight percent of a non-aesthetic excipient. The compactable granular mixture thus obtained is compressed to form a tablet composition. The present invention also provides tablet compositions produced by the methods of the present invention that are substantially free of excipients.”

REFERENCE NO. A11 (US 6,399,093): “A method and composition for the treatment of musculoskeletal disorders in mammals by the application of a topical composition comprising a permeation enhancing amount of one or more penetration enhancers, and one or more bio-

affecting agents to provide anti-inflammatory relief and analgesia to the applied body part.”

III. No fees are believed to be due in connection with these materials. This Information Disclosure Statement is being filed prior to receipt of an official Office Action.

Date: March 17, 2004


Wendy Buskop
Patent Attorney
Reg. 32,202

Please send correspondence to:

Wendy K. B. Buskop
Buskop Law Group PC
1717 St. James Place, Suite 500
Houston, Texas 77056
(713) 403-7411

Application Serial No.: 10/725,608
Attorney Docket No.: 1190.14

Form PTO 1449	U.S. Department of Commerce Patent and Trademark Office	Serial No.: 10/725,608	Group Art Unit: 1614
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Filing Date: 12/02/2003	
		Applicant(s): Kenneth A. Martin and Teresa Leigh Barr	
		Atty. Docket No.: 1190.14	

A REFERENCE - U.S. PATENT DOCUMENTS

Document Number	Examiner Initial*	Patent Number	Date	Name	Class	Sub Class	Filing Date If Appropriate
A1		3,686,406	08/22/1972	Sherlock	424	266	09/18/1970
A2		4,616,039	10/29/1986	Herschler	514	711	04/29/1985
A3		4,621,137	11/4/1986	Miyake, et al.	536	5	12/16/1983
A4		5,827,834	10/27/1998	Falk, et al.	514	54	08/05/1994
A5		5,852,002	12/22/1998	Falk, et al.	514	54	06/05/1995
A6		5,916,565	06/29/1999	Rose, et al.	424	756	03/07/1997
A7		5,929,048	07/27/1999	Falk, et al.	514	54	06/05/1995
A8		5,932,560	08/03/1999	Falk, et al.	514	54	06/05/1995
A9		6,194,392	02/27/2001	Falk, et al.	514	54	08/07/1995
A10		6,358,526	03/19/2002	Mergen, et al.	424	464	08/16/2000
A11		6,399,093	06/04/2002	Petrus	424	448	05/19/1999

B REFERENCE - FOREIGN PATENT DOCUMENTS

Document Number	Examiner Initial*	Patent Number	Date	Country	Class	Sub Class	Translation	
							Yes	No
B1								

C REFERENCE - OTHER DOCUMENTS (Including Author, Title, Date, Pages, Etc.)

Document Number	Examiner Initial*	Other Documents Citation
C1		

Examiner:

Date Considered:

*Examiner:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

